Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Aug 1;40(10):451.e1–451.e8. doi: 10.1016/j.urolonc.2022.07.015

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 Elsevier Inc. All rights reserved.

Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

PMC Copyright notice

Fig 2 — Anti-SARS-CoV-2 S IgG titer in patients with prostate cancer according to concomitant steroid use. A: Distribution of patients. B Comparison of the antibody titer ≥15 U/mL rate between patients with and without concomitant steroid use. C: Association of antibody titer and postvaccine periods according to concomitant steroid use. D: Comparison of the background between patients with antibody titer <15 and ≥15 U/mL among the patients with concomitant steroid use.